Bi Hongyan, Hojo Kaori, Watanabe Masashi, Yee Christina, Maski Kiran, Saba Sadaf, Graff-Radford Jonathan, Machulda Mary M, St Louis Erik K, Humes Ilona Spitsyna, Flanagan Eoin P, Nicolau Stefan, Jones David T, Patterson Marc C, Kotagal Suresh, Raz Yael, Niu Zhiyv, Li Jun, Klein Christopher J
Department of Neurology (H.B., J.G.-R., E.K.S.L., E.P.F., S.N., D.T.J., M.C.P., S.K., C.J.K.), Mayo Clinic, Rochester, MN; Department of Neurology (H.B.), Beijing Friendship Hospital, China; Division of Neuropsychiatry (K.H.), Harima Sanatorium, Hyogo, Japan; Department of Neurology (M.W.), Ehime Prefectural Central Hospital, Matsuyama, Japan; Harvard Medical School (C.Y., K.M.), Boston Children's Hospital, MA; Center for Molecular Medicine and Genetics (S.S.), School of Medicine, Wayne State University, Detroit, MI; Department of Psychology (M.M.M.), Mayo Clinic, Rochester, MN; Atrium Health (I.S.H.), Neurosciences Institute, Concord, NC; Deapartment of Head and Neck Surgery (Y.R.), Oregon Health and Science University, Portland; Department of Laboratory Medicine and Pathology (Z.N., C.J.K.), Mayo Clinic, Rochester, MN; and Department of Neurology and Translational Neuroscience Initiative (J.L.), School of Medicine. Wayne State University, Detroit, MI.
Neurol Genet. 2020 Jun 12;6(4):e456. doi: 10.1212/NXG.0000000000000456. eCollection 2020 Aug.
To report novel causal mutations, expanded clinical phenotypes, and clinical management of DNA methyltransferase 1 (DNMT1)-complex disorder.
Neurophysiologic testing, imaging, and genetic findings were summarized in clinical context for 5 cases with DNMT1-complex disorder.
We identified 2 novel DNMT1 mutations (p.E510K and p.P1546A) by whole-exome sequencing (WES). Case 1 (p.E510K) presented with childhood ataxia, treatment-refractory seizures, and rapid cognitive decline in his 50s. Case 2 also had childhood onset and presented with seizures, language regression, hearing loss, narcolepsy with cataplexy symptoms, optic atrophy, sensory neuropathy, and hypogammaglobulinemia requiring IV immunoglobulin. Case 2 (p.P1546A) was identified with a de novo and the first mutation residing outside the targeting sequence domain. Case 3 (p.A570V) had paralytic asymmetric onset attacks triggered by emotionality and lasting sometimes for weeks. Neuropsychological testing showed executive dysfunction localizing to frontosubcortical and frontoparietal structures. He gradually developed left predominant brain atrophy. MRI showed T2 hyperintense lesions that enhanced on T1 postgadolinium images, and brain PET showed hypometabolism in atrophied regions. Case 4 (p.T497P) underwent left cochlear implant, resulting in significant hearing improvements at all tested frequencies (250-6,000 Hz). Case 5 (p.Y511H) had profound gait ataxia with posterior column atrophy of the spinal cord and abnormal evoked potentials primarily affecting the fasciculus gracilis.
Broader application of WES further expands genotype-phenotype correlations of DNMT1-complex disorder. Two mutations are identified with early childhood onsets. The expanded new phenotypes include asymmetric brain hemiatrophy with parenchymal gadolinium enhancement, spinal cord atrophy, prolonged cataplectic spells, and hypogammaglobulinemia. Hearing loss treatment by cochlear implantation is helpful and should be considered.
报告DNA甲基转移酶1(DNMT1)复合症的新致病突变、扩展的临床表型及临床管理。
对5例DNMT1复合症患者的神经生理学检查、影像学及遗传学结果进行临床背景总结。
通过全外显子组测序(WES)我们鉴定出2个新的DNMT1突变(p.E510K和p.P1546A)。病例1(p.E510K)表现为儿童期共济失调、难治性癫痫发作,50多岁时认知快速衰退。病例2也为儿童期起病,表现为癫痫发作、语言倒退、听力丧失、发作性睡病伴猝倒症状、视神经萎缩、感觉神经病变及需静脉注射免疫球蛋白的低丙种球蛋白血症。病例2(p.P1546A)为新发突变且是首个位于靶向序列结构域之外的突变。病例3(p.A570V)有由情绪引发的麻痹性不对称发作,有时持续数周。神经心理学测试显示执行功能障碍定位于额颞叶皮质下和额顶叶结构。他逐渐出现以左侧为主的脑萎缩。MRI显示T2高信号病变在T1增强后图像上强化,脑PET显示萎缩区域代谢减低。病例4(p.T497P)接受了左侧人工耳蜗植入,所有测试频率(250 - 6000Hz)的听力均有显著改善。病例5(p.Y511H)有严重的步态共济失调,伴有脊髓后柱萎缩及主要影响薄束的异常诱发电位。
WES的更广泛应用进一步扩展了DNMT1复合症的基因型 - 表型相关性。鉴定出两个儿童期起病的突变。扩展的新表型包括伴有实质钆增强的不对称脑半萎缩、脊髓萎缩、延长的猝倒发作及低丙种球蛋白血症。人工耳蜗植入治疗听力丧失是有帮助的,应予以考虑。